{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidrxfkrbr3dhb2rjzcbrscwi2sbi6togffgthzd7kof4ewwqpfvcu",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mnjna7pvmiy2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreih5iz63mgfuuuzqx6del4jzxu7sk7f7hnveecaa5c6fsezmrjjxcq"
    },
    "mimeType": "image/webp",
    "size": 95030
  },
  "path": "/releases/2026/06/260604044247.htm",
  "publishedAt": "2026-06-04T09:18:44.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.",
  "title": "Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival"
}